Nurse Practitioner · Richmond, VA
NPI
1184708265
Since 2006
Specialty
Nurse Practitioner
Code 363L00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1250 E Marshall St, Internal Medicine/Infectious Disease
Richmond, VA, 23298
Phone (804) 828-5914
Groups this clinician bills Medicare through
Medicare paid, 2024
$2,081
44 services
Medicare patients, 2024
18
Average age 65
Drug cost, 2024
$4.1M
1,558 prescriptions
Company payments, 2025
$28K
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Denese C Gomes was code 99214 (office e&m - established), 20 times for 14 patients. In total Denese C Gomes billed 44 services in 3 codes, and Medicare paid $2,081.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 20 | 14 | $47.25 | $945 |
By year: 2022 $2,818 for 70 services; 2023 $1,646 for 33 services; 2024 $2,081 for 44 services.
Medicare prescription drug claims, 2024
In 2024, the drug Denese C Gomes prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 269 prescriptions and refills. In total Denese C Gomes wrote 1,558 Medicare prescriptions that cost $4.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 269 | 271 | 33 | $1.1M |
| Tivicay Dolutegravir Sodium | 237 | 237 | 27 | $555K |
| Dovato Dolutegravir Sodium/Lamivudine | 175 | 175 | 19 | $517K |
| Descovy Emtricitabine/Tenofov Alafenam | 124 | 124 | 12 | $263K |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 100 | 100 | Under 11 | $343K |
| Pifeltro Doravirine | 98 | 98 | 13 | $168K |
| Prezcobix Darunavir/Cobicistat | 88 | 88 | Under 11 | $201K |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | 63 | 63 | Under 11 | $219K |
| Juluca Dolutegravir/Rilpivirine | 49 | 49 | Under 11 | $165K |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 44 | 44 | Under 11 | $206K |
| Isentress Raltegravir Potassium | 33 | 33 | Under 11 | $74K |
| Evotaz Atazanavir Sulfate/Cobicistat | 27 | 27 | Under 11 | $45K |
| Cabenuva Cabotegravir/Rilpivirine | 26 | 41 | Under 11 | $137K |
| Vitamin D2 Ergocalciferol (Vitamin D2) | 26 | 28 | Under 11 | $43.08 |
| Abacavir-Lamivudine Abacavir Sulfate/Lamivudine | 22 | 22 | Under 11 | $19K |
Brand drugs: 1,366 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Denese C Gomes $28K ($28K in general payments such as food, travel and fees) from 2 companies. The largest payer was ViiV Healthcare Company with $20K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.